Latest News

siRNAgen Therapeutics, a leading biotech in the RNAi therapeutics space, is pleased to announce the expansion of its advisory board with the inclusion of distinguished scientific and strategic experts.

Novel siRNA Immunology Drug SRN-001 Breaks New Ground in with Phase 1 Trials in Australia, Leveraging Proprietary SAMiRNA™ Technology for Extrahepatic Delivery

In a recent interview with DeciBio, June Park, CEO of siRNAgen, covered a wide range of topics such as the rapid growth in the siRNA market, expanding RNAi indication areas, and rise of globalization

Johnson & Johnson Innovation LLC and Janssen Korea Ltd. Announce siRNAgen as an Awardee of the Seoul Innovation QuickFire Challenge: Scientific Advancements of Tomorrow in Collaboration with Seoul Metropolitan Government and Korea Health Industry Development Institute

siRNAgen Therapeutics has been selected to join the Endless Frontier Labs 2022-2023 cohort. This year’s 75 ground-breaking companies were selected amongst a competitive pool of over 1,000 applicants. siRNAgen will be joining as one of 26 that have been selected for the Life Sciences Track.

​